Next CBD Product With False Claims Gets FTC Investigation, Not A Warning Letter
"Warning letter phase is over ... We will be opening investigations and we will target companies making disease claims for CBD products," says FTC attorney Rich Cleland. Agency also looking to hold retailers responsible for third-party vendors' false claims.
You may also be interested in...
In addition to FDA and FTC attention, pediatric claims by Rooted Apothecary could get attention of US lawmakers, who FDA is asking to authorize it to more directly enforce against adulterated supplements. Violative claims include “Increasing evidence suggests that CBD oil is a powerful option for pain and autism. It seems like an attractive and safe option for children.”
FTC warned firms selling CBD oils, creams, capsules and gummies with common advertising theme emphasizing ingredient "as a treatment or cure for serious diseases." Some ads specified conditions including Alzheimer’s, multiple sclerosis, epilepsy, heart disease and stroke, claims likely to get FDA's attention, too.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.